Prevalence of drug interactions in hospitalized elderly patients: a systematic review

Luciana Mello de Oliveira 1,2; Juliana do Amaral Carneiro Diel1; Alessandra Nunes3; Tatiane da Silva Dal Pizzol 1,2,3

1Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul.
2Programa de Pós-Graduação em Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul.
3Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul.

Corresponding author: Tatiane da Silva Dal Pizzol - tatiane.silva@ufrgs.br
**Supplementary Figure 1:** Quality Assessment of the reviewed studies and risk of bias. Items were answered as yes (+), no (-), unclear (U), and not applicable to the study (NA). One study was reported in Persian, and other study was an abstract from scientific meeting; in both cases, it was not possible to fully evaluate the items, and in these cases it was classified as “other”.

```
1) Define the source of information (survey, record review)  0.00%  20.00%  40.00%  60.00%  80.00%  100.00%
2) List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications
3) Indicate time period used for identifying patients
4) Indicate whether or not subjects were consecutive if not population-based
5) Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants
6) Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements)
7) Explain any patient exclusions from analysis
8) Describe how confounding was assessed and/or controlled.
9) If applicable, explain how missing data were handled in the analysis
10) Summarize patient response rates and completeness of data collection
11) Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained
```